Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Catalent stock | 91.26

Own Catalent stock in just a few minutes.

Fact checked

Catalent, Inc is a drug manufacturers—specialty & generic business based in the US. Catalent shares (CTLT) are listed on the NYSE and all prices are listed in US Dollars. Catalent employs 13,900 staff and has a trailing 12-month revenue of around USD$3.1 billion.

How to buy shares in Catalent

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Catalent. Find the stock by name or ticker symbol: CTLT. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Catalent reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$91.26, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Catalent, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Catalent. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

How has coronavirus impacted Catalent's share price?

Since the stock market crash in March caused by coronavirus, Catalent's share price has had significant positive movement.

Its last market close was USD$91.26, which is 35.37% up on its pre-crash value of USD$58.98 and 194.01% up on the lowest point reached during the March crash when the shares fell as low as USD$31.04.

If you had bought USD$1,000 worth of Catalent shares at the start of February 2020, those shares would have been worth USD$659.99 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$1,480.24.

Catalent share price

Use our graph to track the performance of CTLT stocks over time.

Catalent shares at a glance

Information last updated 2020-10-20.
Latest market close USD$91.26
52-week range USD$31.04 - USD$96.38
50-day moving average USD$87.3966
200-day moving average USD$78.1007
Wall St. target price USD$102.3
PE ratio 81.0526
Dividend yield N/A (0%)
Earnings per share (TTM) USD$1.14

Buy Catalent shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Vanguard
$0
Stocks, Mutual funds, ETFs, Forex
$1
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
0%
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
$0
or $25 broker-assisted
Stocks
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Catalent stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Catalent price performance over time

Historical closes compared with the close of $91.26 from 2020-10-19

1 week (2020-11-23) -8.56%
1 month (2020-10-30) 3.98%
3 months (2020-08-28) 4.11%
6 months (2020-05-29) 17.41%
1 year (2019-11-29) 75.53%
2 years (2018-11-30) 130.16%
3 years (2017-11-30) 129.35%
5 years (2015-11-30) 227.68%

Is Catalent under- or over-valued?

Valuing Catalent stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Catalent's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Catalent's P/E ratio

Catalent's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 81x. In other words, Catalent shares trade at around 81x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Catalent's PEG ratio

Catalent's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 3.0997. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Catalent's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Catalent's EBITDA

Catalent's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$663.5 million.

The EBITDA is a measure of a Catalent's overall financial performance and is widely used to measure a its profitability.

Catalent financials

Revenue TTM USD$3.1 billion
Operating margin TTM 13.24%
Gross profit TTM USD$983.3 million
Return on assets TTM 3.67%
Return on equity TTM 7.62%
Profit margin 7.13%
Book value $17.807
Market capitalisation USD$15 billion

TTM: trailing 12 months

Shorting Catalent shares

There are currently 1.6 million Catalent shares held short by investors – that's known as Catalent's "short interest". This figure is 23.9% up from 1.3 million last month.

There are a few different ways that this level of interest in shorting Catalent shares can be evaluated.

Catalent's "short interest ratio" (SIR)

Catalent's "short interest ratio" (SIR) is the quantity of Catalent shares currently shorted divided by the average quantity of Catalent shares traded daily (recently around 2.7 million). Catalent's SIR currently stands at 0.59. In other words for every 100,000 Catalent shares traded daily on the market, roughly 590 shares are currently held short.

However Catalent's short interest can also be evaluated against the total number of Catalent shares, or, against the total number of tradable Catalent shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Catalent's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Catalent shares in existence, roughly 10 shares are currently held short) or 0.0129% of the tradable shares (for every 100,000 tradable Catalent shares, roughly 13 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Catalent.

Find out more about how you can short Catalent stock.

Catalent share dividends

We're not expecting Catalent to pay a dividend over the next 12 months.

Catalent share price volatility

Over the last 12 months, Catalent's shares have ranged in value from as little as $31.04 up to $96.38. A popular way to gauge a stock's volatility is its "beta".

CTLT.US volatility(beta: 1.58)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Catalent's is 1.5786. This would suggest that Catalent's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Catalent overview

Catalent, Inc., together with its subsidiaries, provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics segment provides biologic cell-line; develops and manufactures cell therapy and viral vector gene therapy; formulation, development, and manufacturing for parenteral dose forms, including prefilled syringes, vials, and cartridges; and analytical development and testing services. The Oral and Specialty Delivery segment offers formulation, development, and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. This segment also offers oral delivery solutions platform comprising pre-clinical screening, formulation, analytical development, and current good manufacturing practices services. The Clinical Supply Services segment offers manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics clinical trials. It also offers FastChain demand-led clinical supply services. The company serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. It has a collaboration with the Janssen Pharmaceutical Companies; and a partnership with Arcturus Therapeutics Holdings Inc. to support the manufacture of LUNAR-COV19. Catalent, Inc. was founded in 2007 and is headquartered in Somerset, New Jersey.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site